NYSE:ABBVAbbVie Stock Price, Forecast & News

AbbVie's stock was trading at $84.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ABBV shares have increased by 9.2% and is now trading at $92.67.
View which stocks have been most impacted by COVID-19.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for AbbVie.

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, November 6th 2020.
View our earnings forecast for AbbVie.

AbbVie Inc (NYSE:ABBV) released its quarterly earnings data on Friday, July, 31st. The company reported $2.34 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $2.20 by $0.14. The business had revenue of $10.43 billion for the quarter, compared to analysts' expectations of $10.14 billion. AbbVie had a net margin of 19.20% and a negative return on equity of 628.57%. The firm's revenue was up 26.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.26 earnings per share.
View AbbVie's earnings history.

AbbVie announced a quarterly dividend on Wednesday, June 17th. Investors of record on Wednesday, July 15th will be given a dividend of $1.18 per share on Friday, August 14th. This represents a $4.72 dividend on an annualized basis and a dividend yield of 5.09%. The ex-dividend date is Tuesday, July 14th.
View AbbVie's dividend history.

AbbVie announced that its board has authorized a stock repurchase program on Thursday, December 13th 2018, which authorizes the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 3.8% of its shares through open market purchases. Shares buyback programs are usually an indication that the company's management believes its stock is undervalued.

AbbVie issued an update on its FY20 earnings guidance on Friday, July, 31st. The company provided earnings per share (EPS) guidance of $10.35-10.45 for the period, compared to the Thomson Reuters consensus estimate of $10.51.

17 brokerages have issued twelve-month price targets for AbbVie's stock. Their forecasts range from $90.00 to $127.00. On average, they anticipate AbbVie's stock price to reach $107.00 in the next twelve months. This suggests a possible upside of 15.5% from the stock's current price.
View analysts' price targets for AbbVie.

Media coverage about ABBV stock has trended extremely negative on Thursday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AbbVie earned a coverage optimism score of -4.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days.
View the latest news about AbbVie.

AbbVie saw a decrease in short interest in May. As of May 15th, there was short interest totaling 24,800,000 shares, a decrease of 70.9% from the April 30th total of 85,240,000 shares. Based on an average trading volume of 13,470,000 shares, the days-to-cover ratio is presently 1.8 days.
View AbbVie's Short Interest.

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Bristol-Myers Squibb (BMY), AT&T (T), Rogers Communications (RCI) and Open Text (OTEX).

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie's stock is owned by a number of institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (1.21%), Sumitomo Mitsui Trust Holdings Inc. (0.55%), Swiss National Bank (0.47%), PNC Financial Services Group Inc. (0.30%), California Public Employees Retirement System (0.23%) and New York State Common Retirement Fund (0.23%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and William J Chase.
View institutional ownership trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including LSV Asset Management, Toronto Dominion Bank, Russell Investments Group Ltd., Bank of Nova Scotia, Victory Capital Management Inc., American International Group Inc., ProShare Advisors LLC, and Hamlin Capital Management LLC. Company insiders that have sold AbbVie company stock in the last year include Carlos Alban, Jeffrey Ryan Stewart, and Timothy J Richmond.
View insider buying and selling activity for AbbVie.

ABBV stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Healthcare of Ontario Pension Plan Trust Fund, Sumitomo Mitsui Trust Holdings Inc., Swiss National Bank, Newport Trust Co, First Trust Advisors LP, California Public Employees Retirement System, and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin, and William J Chase.
View insider buying and selling activity for AbbVie.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ABBV stock can currently be purchased for approximately $92.67.

AbbVie has a market capitalization of $163.55 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.

The official website for AbbVie is www.abbvie.com.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.